Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil

“Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.”